Wireless Implant Lowers Blood Sugar in Mice by Converting Glucose for Excretion

A wireless implant that converts glucose into a form the kidneys can remove produced rapid blood sugar reductions in mice with type 2 diabetes and obesity. The approach bypasses insulin and living cells, but whether it can handle human glucose loads safely is still unknown. It’s an intriguing change in strategy: instead of helping the body use glucose, the device aims to turn some of it into waste. That shift brings a different set of questions about capacity, kidney function and how precisely the system can control glucose removal.

In the study, switching on the device returned high blood sugar to normal within 60 to 90 minutes. After six weeks, treated mice had lost as much as 10 percent of their body weight and showed lower blood triglycerides. The findings were reported October 22 in Science. Those results suggest that removing glucose may affect more than a single blood test, though the study’s mouse results don’t establish how the approach would perform in people or over longer periods.

Turning glucose into a waste product

The implant is about 3 centimeters long. Its catalyst combines gold flakes and platinum particles on a porous graphite base. When powered, it converts glucose into gluconate, which the kidneys can excrete in urine. In practical terms, the device acts as a chemical sink for glucose: it changes the molecule into a form the body can clear rather than relying on insulin to help move glucose into cells.

That process may also change how the body gets energy. With less glucose available, it could draw more heavily on stored fat; the treated mice had elevated blood levels of ketones and other products of fat breakdown. “This system kind of targets the root cause, which is the energy surplus by glucose in the body,” says study coauthor Martin Fussenegger, a bioengineer at ETH Zurich. The metabolic changes are consistent with that explanation, but they don’t yet show how much glucose the device would need to remove to produce the same effects in a person.

The device is designed to respond automatically. A wearable glucose monitor sends readings through a smartphone, which switches the implant on when blood sugar rises and off when levels return to a safer range. That feedback loop matters because the implant’s output needs to track changing glucose levels rather than run continuously. The automated setup operated for two weeks in eight mice. The catalyst remained active after as long as three months under the animals’ skin, although the researchers haven’t established the lifetime of the full system. A working catalyst is only one part of the system; the monitor, wireless link and control process also have to keep functioning.

Safety and scale remain unresolved

The results point to a different way of managing glucose than conventional type 2 diabetes treatments, including insulin and GLP-1 drugs, which require careful dosing. Existing experimental implants still depend on insulin, says Fussenegger. The new device is intended to remove glucose from the body without adding drugs, genes or cells. That distinction is more significant than it looks: changing what the body clears could avoid some treatment steps while creating new demands on the organs doing the clearing.

That distinction also raises questions about what happens to the byproduct. David Klonoff, an endocrinologist at Sutter Mills-Peninsula Medical Center in Burlingame, Calif., who wasn’t involved in the study, calls the method potentially promising but says risks need to be assessed before human testing. The kidneys’ ability to clear gluconate needs study, he says: accumulation could disturb acid-base balance, while excretion might deplete electrolytes such as sodium and potassium. These are potential concerns, not reported harms in the mice; the point is that turning glucose into a waste product shifts part of the safety question to how the body handles that product.

Capacity is another hurdle. People consume about 250 grams of carbohydrates a day, compared with roughly two grams for mice, Klonoff estimates. An implant sized for people could therefore need to be much larger or use multiple devices. In a laboratory test, a larger version cleared nearly all glucose from about five liters of solution, approximately an adult’s blood volume, but it did not remove a full day’s glucose intake. And this is the part most people overlook: clearing glucose from a volume of fluid in a lab doesn’t show that an implant can keep pace with the continual arrival of glucose from meals and normal metabolism. The numbers here are underwhelming against that daily load.

What the next animal studies need to show

Fussenegger’s team plans to test the system in pigs and sheep before considering human trials. Those studies will need to establish both safety and enough capacity for larger bodies; until then, the weight and blood sugar effects remain findings in mice. Larger animals could help reveal whether the device’s chemistry, control system and glucose removal rate work together at a more demanding scale. They’ll also give researchers a chance to examine whether gluconate clearance and electrolyte balance remain manageable over time.

If you’re working in this space, the key question is whether the system can remove enough glucose to matter without creating a new metabolic burden. The concept is clear; the operating limits aren’t. For now, a promising mouse result. Human usefulness will depend on evidence that the implant can sustain its effect safely and at a scale the mouse experiments haven’t tested.